Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Masato Fukae"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 10, Pp 1655-1669 (2024)
Abstract Valemetostat is an oral inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1 approved in Japan for the treatment of adult T‐cell leukemia/lymphoma (ATLL). To support the approved daily dose of 200 mg and inform dose adjustments in patie
Externí odkaz:
https://doaj.org/article/c41d9e15557546d19891d4fdc2b0a0ed
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 10, Pp 1641-1654 (2024)
Abstract Valemetostat is an EZH2/1 inhibitor that has been approved in Japan for the treatment of patients with relapsed/refractory adult T‐cell leukemia/lymphoma, based mainly on results from a single‐arm phase II trial. It is currently under in
Externí odkaz:
https://doaj.org/article/fc97c850f0cc4f17b8c5def4c6355633
Autor:
Ichiro Ieiri, Yushi Kashihara, Jun Ichiro Koga, Tetsuya Matoba, Masato Fukae, Junji Kishimoto, Shin Irie, Koji Todaka, Masanari Shiramoto, Kaku Nakano, Kensuke Egashira
Publikováno v:
International Heart Journal. 59:1015-1025
Pulmonary hypertension (PH) is a disease with poor prognosis, caused by the obstruction/stenosis of small pulmonary arteries. Statin is known to have vasodilating and anti-inflammatory property and is considered to be a candidate of therapeutic agent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef2e7292173eecd27a576e17321f710c
https://doi.org/10.1536/ihj.17-555
https://doi.org/10.1536/ihj.17-555
Autor:
Noritomo Izumi, Masato Fukae, Shin Irie, Hiroyuki Kusuhara, Shunji Matsuki, Takeshi Hirota, Kazuya Maeda, Yuichi Sugiyama, Takashi Yoshikado, Ichiro Ieiri, Miyuki Kimura, Yushi Kashihara
Publikováno v:
Journal of Pharmaceutical Sciences. 106:2688-2694
The aims of this study were (1) to investigate the effects of atorvastatin (10 mg, therapeutic dose) and grapefruit juice (GFJ), inhibitors of OATP2B1, on the pharmacokinetics of substrates for OATP2B1 and BCRP under oral small-dosing conditions (300
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::974c9daed0baf6f041e544b093ed2e7c
https://doi.org/10.1016/j.xphs.2017.03.010
https://doi.org/10.1016/j.xphs.2017.03.010
Autor:
Ichiro Ieiri, Koichi Takayama, Yoichi Nakanishi, Masato Fukae, Yoshimasa Shiraishi, Takeshi Hirota, Yuka Sasaki, Mika Yamahashi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 78:1013-1023
Docetaxel is used to treat many cancers, and neutropenia is the dose-limiting factor for its clinical use. A population pharmacokinetic–pharmacodynamic (PK–PD) model was introduced to predict the development of docetaxel-induced neutropenia in Ja
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da32ec6d3e33f82f6eb6926ba9455f51
https://doi.org/10.1007/s00280-016-3157-9
https://doi.org/10.1007/s00280-016-3157-9
Autor:
Hiroko Nomura, Mai Ezaki, Takeshi Hirota, Makoto Kakara, Sunao Matsubayashi, Masato Fukae, Ichiro Ieiri, Masaaki Hirakawa
Publikováno v:
Journal of Diabetes and its Complications. 30:1282-1286
Aim To develop a population pharmacodynamic (PPD) model describing the time course for the hemoglobin A1c (HbA1c)-lowering effects of adding treatment of DPP-4 inhibitors and to assess the efficacy of combination therapy in type 2 diabetes mellitus p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdab2e98b0d40dc3450b8f865f16d35f
https://doi.org/10.1016/j.jdiacomp.2016.06.009
https://doi.org/10.1016/j.jdiacomp.2016.06.009
Autor:
Kaku, Nakano, Tetsuya, Matoba, Jun-Ichiro, Koga, Yushi, Kashihara, Masato, Fukae, Ichiro, Ieiri, Masanari, Shiramoto, Shin, Irie, Junji, Kishimoto, Koji, Todaka, Kensuke, Egashira
Publikováno v:
International heart journal. 59(5)
Pulmonary hypertension (PH) is a disease with poor prognosis, caused by the obstruction/stenosis of small pulmonary arteries. Statin is known to have vasodilating and anti-inflammatory property and is considered to be a candidate of therapeutic agent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ed78f4b9af4bf7bf5f8ede7972cfe890
https://pubmed.ncbi.nlm.nih.gov/30158384
https://pubmed.ncbi.nlm.nih.gov/30158384
Autor:
Ryoko Kinoshita, Kunio Maema, Makoto Kakara, Yoko Tamaki, Shota Muraki, Ichiro Ieiri, Takeshi Hirota, Yushi Kashihara, Masato Fukae
Publikováno v:
Drug metabolism and pharmacokinetics. 33(6)
The objective of the present study was to develop a population pharmacodynamic (PPD) model to describe the glycated hemoglobin (HbA1c)-lowering effects of metformin in type 2 diabetes mellitus patients with and without secondary failure and to charac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c273ad2128eb6868f081ef0c2c68e13d
https://pubmed.ncbi.nlm.nih.gov/30360949
https://pubmed.ncbi.nlm.nih.gov/30360949
Autor:
Ichiro Ieiri, Saki Shigematsu, Hiroshi Takane, Daiki Yamashita, Kuniaki Moriki, Masaaki Hirakawa, Takeshi Hirota, Shota Muraki, Masato Fukae, Makoto Kakara, Miki Shimada
Publikováno v:
Journal of clinical pharmacology. 58(3)
The aim of this study was to develop a population pharmacodynamic (PPD) model to describe uric acid (UA)-lowering effects in patients treated with febuxostat based on electronic medical records in 2 independent hospitals (university and city hospital
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1e8eceec1046214495056a3ecb5b2b1
https://pubmed.ncbi.nlm.nih.gov/29045766
https://pubmed.ncbi.nlm.nih.gov/29045766
Autor:
Hiroko Nomura, Hideki Shimomura, Ichiro Ieiri, Sunao Matsubayashi, Masato Fukae, Makoto Kakara, Takeshi Hirota, Keisuke Gotanda, Masaaki Hirakawa
Publikováno v:
British Journal of Clinical Pharmacology. 78:824-835
Aims HMG-CoA reductase inhibitors are available for use in low density lipoprotein-cholesterol (LDL-C) lowering therapy. The purposes of this study were to develop a population pharmacodynamic (PPD) model to describe the time course for the LDL-C low
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::994a441120547ae1db9d4071b4190ed0
https://doi.org/10.1111/bcp.12405
https://doi.org/10.1111/bcp.12405